178 related articles for article (PubMed ID: 37760457)
1. The Association between Immune Checkpoint Proteins and Therapy Outcomes in Acute Myeloid Leukaemia Patients.
Bolkun L; Tynecka M; Walewska A; Bernatowicz M; Piszcz J; Cichocka E; Wandtke T; Czemerska M; Wierzbowska A; Moniuszko M; Grubczak K; Eljaszewicz A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760457
[TBL] [Abstract][Full Text] [Related]
2. Effects of Combinatory In Vitro Treatment with Immune Checkpoint Inhibitors and Cytarabine on the Anti-Cancer Immune Microenvironment in De Novo AML Patients.
Bołkun Ł; Starosz A; Krętowska-Grunwald A; Wasiluk T; Walewska A; Wierzbowska A; Moniuszko M; Grubczak K
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275902
[TBL] [Abstract][Full Text] [Related]
3. Expression patterns of immune checkpoints in acute myeloid leukemia.
Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
[TBL] [Abstract][Full Text] [Related]
4. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
5. Expression of PD-L1 on regulatory B cells in patients with acute myeloid leukaemia and its effect on prognosis.
Shi Y; Liu Z; Wang H
J Cell Mol Med; 2022 Jun; 26(12):3506-3512. PubMed ID: 35610758
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia.
Kang SH; Hwang HJ; Yoo JW; Kim H; Choi ES; Hwang SH; Cho YU; Jang S; Park CJ; Im HJ; Seo JJ; Kim N; Koh KN
Anticancer Res; 2019 Oct; 39(10):5531-5539. PubMed ID: 31570447
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Saxena K; Herbrich SM; Pemmaraju N; Kadia TM; DiNardo CD; Borthakur G; Pierce SA; Jabbour E; Wang SA; Bueso-Ramos C; Loghavi S; Tang G; Cheung CM; Alexander L; Kornblau S; Andreeff M; Garcia-Manero G; Ravandi F; Konopleva MY; Daver N
Cancer; 2021 Oct; 127(20):3761-3771. PubMed ID: 34171128
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis reveals distinct molecular, clinical, and immunological features of B7-H3 in acute myeloid leukemia.
Zhang LY; Jin Y; Xia PH; Lin J; Ma JC; Li T; Liu ZQ; Xiang HL; Cheng C; Xu ZJ; Zhou H; Qian J
Cancer Med; 2021 Nov; 10(21):7831-7846. PubMed ID: 34562306
[TBL] [Abstract][Full Text] [Related]
12. B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.
Antohe I; Dǎscǎlescu A; Dǎnǎilǎ C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Pavel M; Cianga P
Front Oncol; 2020; 10():264. PubMed ID: 32231996
[TBL] [Abstract][Full Text] [Related]
13. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
14. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
16. One Year Disease Free Survival In Acute Myeloid Leukemia Patients After Induction Remission.
Shaikh MR; Haider G; Shahid A; Rahool R; Beg S; Memon P; ; Nouman M
J Ayub Med Coll Abbottabad; 2021; 33(3):475-479. PubMed ID: 34487660
[TBL] [Abstract][Full Text] [Related]
17. Expression characteristic of
Zhang W; Zhang L; Qian J; Lin J; Chen Q; Yuan Q; Zhou J; Zhang T; Shi J; Zhou H
Bioengineered; 2021 Dec; 12(2):11987-12002. PubMed ID: 34787059
[No Abstract] [Full Text] [Related]
18. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
Ge MJ; Xu KL; Xu T; Tang YN; Li ZY; Yan ZL; Sun HY; Cheng H; Zhu F; Sang W; Huang YH; Qiu TT; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis.
Lee JH; Kim YJ; Ryu HW; Shin SW; Kim EJ; Shin SH; Park JY; Kim SY; Hwang CS; Na JY; Shin DH; Kim JY; Lee HJ
Diagn Pathol; 2023 Mar; 18(1):36. PubMed ID: 36894965
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]